196 related articles for article (PubMed ID: 16313325)
1. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients.
Tierce JC; Porterfield-Baxa J; Petrilla AA; Kilburg A; Ferguson RM
Clin Transplant; 2005 Dec; 19(6):779-84. PubMed ID: 16313325
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil.
Hardinger KL; Brennan DC; Lowell J; Schnitzler MA
Transpl Int; 2004 Nov; 17(10):609-16. PubMed ID: 15517170
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.
Sollinger HW; Sundberg AK; Leverson G; Voss BJ; Pirsch JD
Transplantation; 2010 Feb; 89(4):446-51. PubMed ID: 20177347
[TBL] [Abstract][Full Text] [Related]
4. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure.
Bunnapradist S; Lentine KL; Burroughs TE; Pinsky BW; Hardinger KL; Brennan DC; Schnitzler MA
Transplantation; 2006 Jul; 82(1):102-7. PubMed ID: 16861948
[TBL] [Abstract][Full Text] [Related]
6. The Cost of Gastrointestinal Adverse Events and the Impact of Dose-Reductions/Discontinuations on Acute Rejection in Kidney Transplant Patients of Mycophenolate Mofetil-Related Compared to Enteric-Coated Mycophenolate Sodium: A Pharmacoeconomic Study.
Martinez-Mier G; Salazar-Ramirez A
Transplant Proc; 2016 Mar; 48(2):588-95. PubMed ID: 27110009
[TBL] [Abstract][Full Text] [Related]
7. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
Machnicki G; Ricci JF; Brennan DC; Schnitzler MA
Pharmacoeconomics; 2008; 26(11):951-67. PubMed ID: 18850764
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
[TBL] [Abstract][Full Text] [Related]
9. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.
Cooper M; Deering KL; Slakey DP; Harshaw Q; Arcona S; McCann EL; Rasetto FA; Florman SS
Transplantation; 2009 Aug; 88(4):514-20. PubMed ID: 19696634
[TBL] [Abstract][Full Text] [Related]
10. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
Sabbatini M; Capone D; Gallo R; Pisani A; Polichetti G; Tarantino G; Gentile A; Rotaia E; Federico S
Fundam Clin Pharmacol; 2009 Oct; 23(5):617-24. PubMed ID: 19656208
[TBL] [Abstract][Full Text] [Related]
11. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
Darji P; Vijayaraghavan R; Thiagarajan CM; Sharma RK; Subbarao B; Pishardy R; Dakshinamurthy KV; Vijaykumar R; Abraham G; Bhaskar S; Agarwal L; Shah B; Abraham A; John M; Sampathkumar K; Das T; Umesh L; Sundar S; Ballal H; Jasuja S; Saxena S; Saha TK
Transplant Proc; 2008 Sep; 40(7):2262-7. PubMed ID: 18790208
[TBL] [Abstract][Full Text] [Related]
12. Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies.
Bunnapradist S; Ambühl PM
Clin Transplant; 2008; 22(6):815-21. PubMed ID: 18798850
[TBL] [Abstract][Full Text] [Related]
13. Enteric coating of mycophenolate reduces dosage adjustments.
Brister K; Yau CL; Slakey D
Transplant Proc; 2009 Jun; 41(5):1657-9. PubMed ID: 19545702
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant patients.
Salifu MO; Jindal RM
Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):29-32. PubMed ID: 19371175
[TBL] [Abstract][Full Text] [Related]
15. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium.
Kamar N; Oufroukhi L; Faure P; Ribes D; Cointault O; Lavayssiere L; Nogier MB; Esposito L; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Oct; 20(10):2231-6. PubMed ID: 16046517
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil dose reduction for gastrointestinal intolerance is associated with increased rates of rejection in heart transplant patients.
Galiwango PJ; Delgado DH; Yan R; Kozuszko S; Smith R; Rao V; Ross HJ
J Heart Lung Transplant; 2008 Jan; 27(1):72-7. PubMed ID: 18187090
[TBL] [Abstract][Full Text] [Related]
18. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients.
Sollinger H
Transplant Proc; 2004 Mar; 36(2 Suppl):517S-520S. PubMed ID: 15041399
[TBL] [Abstract][Full Text] [Related]
19. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
[TBL] [Abstract][Full Text] [Related]
20. Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing.
Cooper M; Salvadori M; Budde K; Oppenheimer F; Sollinger H; Zeier M
Transplant Rev (Orlando); 2012 Oct; 26(4):233-40. PubMed ID: 22863029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
